Imaging of mitochondial complex I function in down syndrome
Active Project Grant Awarded Last action
- Award ID
- R21AG086927
- Recipient
-
The General Hospital Corporation UEI FLJ7DQKLL226
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $960,250
Award facts
- Assistance listing
- 93.310 Trans-NIH Research Support
- Completion date 79% complete
- Originally
- Funding agency
- Office of the Director National Institutes of Health, Department of Health and Human Services
- Place of performance
- Charlestown, MA 02129, USA
Award details come from USAspending.gov.
Description
- Abstract
- This new R21 application is submitted in response to RFA-OD-21-007 (investigation of CO-occurring conditions across the lifespan to understand down syndrome (INCLUDE). The overarching goal of this pilot study is to apply and evaluate [18F]-bcpp-EF positron emission tomography (pet) imaging for the in vivo assessment of mitochondrial complex I (MC-I) function in individuals with down syndrome (DS). Impairment or disruption of the electron transport chain (etc) is common in several neurodegenerative diseases. Research has shown that alterations in mitochondrial ATP production and redox homeostasis (that strongly supports neural function) are associated with DS and alzheimer's disease (ad) pathogenesis. The mitochondrial complex I (MC-I) is the first enzyme complex of the etc that plays an important role in oxidative phosphorylation and radical oxygen species (ROS) generation in mitochondria, and IT is the largest complex in the respiratory chain. As a result, there is much interest in potential therapeutics for DS that target MC-I. [18F]-bcpp-EF has been developed as a high-affinity pet radioligand for in vivo imaging of MC-I activity. Prior [18F]-bcpp-EF studies showed its feasibility for in vivo human imaging and robust test- retest performance in healthy controls. [18F]-bcpp-EF studies in mild ad subjects yielded evidence of: [1] reduced MC-I activity in cortical and subcortical brain areas; [2] mitochondrial-related energy failure preceding glycolysis-related FDG hypometabolism in the parahippocampus; and [3] links between reductions in MC-I activity and hypometabolism, atrophy, and cognitive decline, but not AΒ load. Recent [18F]-bcpp-EF studies provide a strong basis for future MC-I imaging studies in DS. Our primary aim is to perform [18F]-bcpp-EF pet imaging in DS individuals and control participants and map the distribution of MC-I activity throughout DS brain and relative to that observed in control subjects. We hypothesize that MC-I activity will be reduced in cortical and subcortical regions of DS subjects (relative to controls) in a manner that exceeds differences in cerebral atrophy. We will generate quantitative and simplified regional [18F]-bcpp-EF outcomes to evaluate the kinetics of nonspecific uptake, and further evaluate potential reference regions (as IT appears that no region is fully devoid of MC- I and cerebellum is an area for which atrophy can be extensive in DS). Maps of MC-I activity will be generated for the DS and controls subjects and corresponding difference maps will be evaluated. Innovation, impact, significance: [18F]-bcpp-EF pet imaging in down syndrome is novel and, to our knowledge, has not yet been demonstrated. This pilot research (and data sharing) has the potential to: [1] provide new in vivo evidence of mitochondrial dysfunction in DS; [2] support future advanced R01 research of mitochondrial energetics in DS; and [3] further inform drug discovery efforts that target MC-I.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $208,750 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $250,500 | |
| Amendment | $250,500 | |
| Original award | $250,500 |
Quick answers
Who received award R21AG086927?
R21AG086927 was awarded to The General Hospital Corporation by National Institute on Aging (National Institutes of Health) on August 1, 2024.
How much is award R21AG086927 worth?
$960,250 has been obligated on R21AG086927.
Which agency awarded R21AG086927?
National Institute on Aging (National Institutes of Health) awarded R21AG086927, with funding from Office of the Director (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award